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Activity-based protein proﬁling (ABPP) is a newly emerging technique that uses active site-
directed probes to monitor the functional status of enzymes. Serine hydrolases are one of
the largest families of enzymes in mammals. More than 200 serine hydrolases have been
identiﬁed, but little is known about their speciﬁc roles. Serine hydrolases are involved in
a variety of physiological functions, including digestion, immune response, blood coagula-
tion, and reproduction. ABPP has been used recently to investigate host–virus interactions
and to understand the molecular pathogenesis of virus infections. Monitoring the altered
serine hydrolases during viral infection gives insight into the catalytic activity of these
enzymes that will help to identify novel targets for diagnostic and therapeutic applica-
tion. This review presents the usefulness of ABPP in detecting and analyzing functional
annotation of host cell serine hydrolases as a result of host–virus interaction.
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ACTIVITY-BASED PROTEIN PROFILING
Most enzymes are tightly regulated post-translationally. Many
enzymes are synthesized as zymogens, which are functionally inac-
tive. Moreover, enzyme functions can be changed by alterations in
pH and binding to inhibitors. Thus, methods that allow direct
quantiﬁcation of protein activities rather than simply protein
abundance are required to delineate distinct protein functions in
physiological and pathological events. Activity-based protein pro-
ﬁling (ABPP) is a chemoproteomic platform for monitoring active
proteins or enzymes. ABPP utilizes chemical probes to interrogate
the functional state of large numbers of enzymes in complex pro-
teomes in vitro or in vivo biological systems. ABPP probes consist
of two key elements: (1) a reactive group/warhead (e.g., small
molecule inhibitors, substrate-based scaffolds, or protein-reactive
molecules) for binding and covalently labeling the active sites of
many members of a given enzyme class (or classes), and (2) a
reporter tag for the detection, enrichment, and/or identiﬁcation
of labeled enzymes from proteomes. A variety of reporter tags are
used inABPP, such as ﬂuorophores (e.g., rhodamine) for visualiza-
tion, biotin for enrichment as well as “clickable” handles, such as
azides and acetylenes for in vivo or in situ labeling of proteins. The
linker region is a ﬂexible chain of varying length and hydropho-
bicity that connects and acts as a spacer between the warhead and
the reporter tag.
Serine hydrolases represent one of the largest and most diverse
classes of enzymes in higher eukaryotes, collectively composing
about 3% of the predicted Drosophila proteome (Rubin et al.,
2000) and about 1% of all predicted expressed human genes (Lan-
der et al., 2001). Serine hydrolases are involved in a variety of
physiological and pathological processes including blood coagula-
tion (Kalafatis et al., 1997), T cell cytotoxicity (Smyth et al., 1996),
inﬂammation (Bonventre et al., 1997), neural plasticity (Yoshida
and Shiosaka, 1999), neurotransmitter catabolism (Taylor, 1991;
Cravatt et al., 1996), peptide/protein processing (Steiner, 1998),
protein/lipid digestion (Lowe, 1997), angiogenesis (Mignatti and
Rifkin, 1996), emphysema (Kato, 1999), and cancer (DeClerck
et al., 1997). Serine hydrolases also perform crucial functions in
bacteria and viruses, where they contribute to pathogen life cycle
(Steuber and Hilgenfeld, 2010), virulence (White et al., 2011), and
drug resistance (Damblon et al., 1996). Most enzymes hydrolyze
metabolites, peptides or post-translational ester and thioester
modiﬁcations on proteins. Because of the biological importance
of serine hydrolases, clinically approved drugs target members
of this enzyme class to treat diseases such as obesity (Henness
and Perry, 2006), diabetes (Thornberry and Weber, 2007), micro-
bial infections (Kluge and Petter, 2010), and Alzheimer’s disease
(Racchi et al., 2004).
Proteolytic cleavages of viral proteins by cellular or viral
proteases are necessary for host cell attachment, invasion, and
reproduction of viral progeny. Host serine proteases are essential
for the inﬂuenza virus life cycle because the viral hemagglutinin is
synthesized as a precursor which requires proteolytic maturation
(Garten and Klenk, 2008). Recently, the non-structural 3 protease
(NS3 – is a chymotrypsin-like serine protease which requires a
polypeptide cofactor NS2B for activation) has been shown to be
responsible for cleavage of the viral polyprotein precursor and to
play a pivotal role in the replication of ﬂaviviruses (Falgout et al.,
1991; Mukhopadhyay et al., 2005; Chappell et al., 2006) includ-
ing Hepatitis C (HCV), West Nile virus, and Dengue virus. NS3
also facilitates viral pathogenicity by cleaving host proteins and
down-regulating the innate immune response of the cell (Failla
et al., 1994; Meylan et al., 2005). In fact, site-directed mutagenesis
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that focused on the NS3 cleavage sites in the polyprotein precursor
abolishes viral infectivity (Chappell et al., 2006). Cell culture mod-
els provided important clues about potential inhibition of several
protease inhibitors against NS3 for Dengue virus and West Nile
virus (Cregar-Hernandez et al., 2011; Steuer et al., 2011). Clini-
cal trials of NS3 serine protease inhibitors showed good success
rates (Lee et al., 2012) as anti-HCV. Therefore, NS3 is one of
the most promising targets for drug development against Fla-
viviridae infections (Kolykhalov et al., 2000; Chappell et al., 2008).
Other serine proteases involved in the pathogenesis and virus life
cycles are being considered as targets for chemotherapy. The cat-
alytic activity of the herpes simplex virus type 1 serine protease is
essential for viral nucleocapsid formation and for viral replication
(Gao et al., 1994). A trypsin-like serine protease is involved in
pseudorabies viral penetration of the basement membrane dur-
ing mucosal invasion (Glorieux et al., 2011). Serine protease
inhibitors inhibit pseudorabies virus invasion in basalmembranes.
A vaccinia virus serine protease inhibitor prevents virus induced
cell fusion (Law and Smith, 1992). Serine protease inhibitor
AEBSF and pAB signiﬁcantly reduce inﬂuenza A virus replication
in mouse models (Bahgat et al., 2011). However, identiﬁcation
of active SHS and their functional characterization are neces-
sary for better understanding the molecular pathogenesis and
development of antiviral strategies.
All serine hydrolases possess a common catalytic mechanism
that involves activation of a conserved serine nucleophile for
attack on a substrate ester/thioester/amide bond to form an acyl-
enzyme intermediate, followed by water-catalyzed hydrolysis of
this intermediate to liberate the product. The greatly enhanced
nucleophilicity of the catalytic serine renders it susceptible to
covalent modiﬁcation by many types of electrophiles, including
ﬂuorophosphonates (FPs) and aryl phosphonates, sulfonyl ﬂuo-
rides, and carbamates (Alexander and Cravatt, 2005; Jessani et al.,
2005; Okerberg et al., 2005). FPs are highly reactive and provide
broad coverage, with the capacity to react with nearly all essen-
tial serine hydrolases (Bachovchin et al., 2010). Therefore, they are
ideal reagents to use for ABPP of serine hydrolases (Liu et al., 1999;
Patricelli et al., 2001). However, certain serine proteases displayed
restricted substrate selectivities that reduce their labeling with FPs.
To address this limitation of FPs, selective inhibitors (e.g., carba-
mates, triazole ureas) have been introduced to probe the function
of individual serine hydrolase in biological systems (Bachovchin
et al., 2010; Adibekian et al., 2011).
ABPP IN HOST VIRUS INTERACTION
Microarray technologies in the ﬁeld of genomics (transcrip-
tomics), and mass spectrometry and bioinformatics technologies
in proteomics, have facilitated the speciﬁc and global analyses of
genes and their expression, and this has accelerated understanding
the molecular basis of disease. These technologies, coupled with
two-dimensional gel electrophoresis,mass spectrometry enhanced
with chromatographic separations such as MudPIT (Shaw et al.,
2008), or isotope coding-ICAT (Yan et al., 2004), iTRAQ (Lu et al.,
2012), and SILAC (Coombs et al., 2010), have provided valu-
able insight into the quantitative differences in protein abundance
during virus infections. However, these methods lack the inher-
ent ability to proﬁle and distinguish proteins according to their
actual biological activities or functional state, which has more
important bearings on understanding the implications of these
macromolecules in vivo (Barglow and Cravatt, 2007). The lack of
functional assessment of these other omic methods has prompted
the development of alternative strategies such as ABPP, for the
discovery and characterization of enzyme activities within highly
complex biological samples.
COMPARATIVE ABPP FOR TARGET DISCOVERY
A typical target discovery experiment would comparatively ana-
lyze two or more proteomes by ABPP to identify enzymes with
differing levels of activity (Figure 1). The differentially expressed
serine hydrolases in healthy and diseased samples can be hypoth-
esized to regulate the host–virus interaction. The testing of such
hypotheses, of course, requires further experimentation for vali-
dation (e.g., functional interference of the target enzyme). ABPP
has been used to proﬁle a number of enzyme classes including pro-
teases, hydrolases, oxidoreductases, and isomerases in the process
of host–virus interaction (Kattenhorn et al., 2005; Schlieker et al.,
2005; Wang et al., 2006; Gredmark et al., 2007; Jarosinski et al.,
2007; Shah et al., 2010). Proﬁling of hydrolases in Huh7 cells repli-
cating HCV identiﬁed CES1 (carboxylesterase 1) as a differentially
active enzyme which has an important role in HCV propagation
(Blais et al., 2010). We have examined the activity of serine hydro-
lases during reovirus, Inﬂuenza A, and Sindbis virus replication
in cell culture in different cell lines. Differential serine hydro-
lase activities were induced by different viruses and alterations
of serine hydrolases were dependent on the time course of viral
infection. Several of these differentially active serine hydrolases
represent possible virus–host interactions that could be targeted
for development of antivirals.
COMPETITIVE ABPP FOR INHIBITOR DISCOVERY
ABPP can also be used as a competitive screen to identify both
reversible and irreversible enzyme inhibitors and also to conﬁrm
target inhibition because inhibitors have the ability to block probe
labeling of enzymes (Kidd et al., 2001; Greenbaum et al., 2002;
Leung et al., 2003; Adibekian et al., 2011). Competitive ABPP has
already led to the discovery of selective serine inhibitors (e.g.,
carbamates, trizole ureas) for several enzymes (e.g., peptidase,
lipases), which have in turn been used to test the function of these
proteins in living systems (Bachovchin et al., 2010; Adibekian et al.,
2011). An alternative omic strategy would be to examine libraries
of commercially available protease inhibitors for their ability to
inhibit a virus’ pathological process; this would potentially lead to
development of novel therapeutic options.
QUANTITATIVE ABPP
Quantiﬁcation of differentially expressed active proteins after
virus infection is essential for better analysis of results, partic-
ularly when examining enzymes. It is difﬁcult to compare the
altered serine hydrolases between healthy and infected samples
by simply visualizing gel images or merely by mass spectrom-
etry. To address this problem an advanced quantitative mass
spectrometry-based method called ABPP-SILAC (stable isotope
labeling with amino acid in cell culture) has been used to iden-
tify alterations in the levels of active enzyme targets (Everley
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FIGURE 1 |When probe is incubated with crude cell lysates (A) or, if
the probe is cell permeable (B), with whole cells the reactive group
speciﬁcally interacts with active site of serine hydrolase (SHs) and forms
a covalent linkage. The labeled proteome can be directly analyzed by
gel image (A), or analyzed by Mass spectrometry following enrichment
of SHs (B).
et al., 2007) and in small molecule-binding proteins in cell lysates
(Ong et al., 2009). Comparative ABPP -SILAC can be used to
quantify more accurately the intricate changes in host proteins
caused by viral infection. Similarly, competitive ABPP-SILAC is
valuable to identify inhibited enzymes during global screening of
inhibitors.
PERSPECTIVE OF VIRUS ABPP FOR SERINE HYDROLASE
Many enzymes and metabolites display difﬁcult physicochemi-
cal properties that complicate their analysis in biological sam-
ples, and many metabolic pathways that enzymes regulate in a
disease-speciﬁc context are not understood. These challenges can
be addressed by applying innovative metabolomics and ABPP
approaches to mapping biochemical pathways that support dis-
ease. Using selective inhibitors developed through competitive
ABPP efforts or RNA interference technology, the function of
an enzyme of interest can be speciﬁcally blocked, and then the
metabolites that the enzyme regulates can be proﬁled. In this man-
ner, not only can the substrates and products of an enzyme in
speciﬁc (patho)physiological contexts be examined, but also the
metabolic networks that the enzyme regulates can be identiﬁed
and annotated. Collectively, this platform will allow identiﬁca-
tion of novel biochemical roles of already characterized enzymes,
or may allow the identiﬁcation of metabolic roles of completely
uncharacterized enzymes.
Understanding the mechanisms by which viruses develop resis-
tance is a vital component of the ﬁght against viral diseases, and
can lengthen the lifespan of existing antivirals. Potentially any
antivirus molecule could be transformed into an activity-based
or afﬁnity-based probe, allowing isolation and characterization of
enzymes that detoxify the antiviral drug.
ABPP with live cell imaging may provide additional insight
into understanding the pathogenesis due to viral infection
(Furman et al., 2009). Identiﬁcation and functional characteriza-
tion of serine hydrolases involved in pathogenesis and virulence of
viruses would be a novel approach to uncover molecular processes
at the basis of viral diseases.
Natural products represent an important treasure box of bio-
logically active molecules, from which many drug candidates have
been developed (Newman and Cragg, 2007). Since a large num-
ber of the proteome remains functionally uncharacterized and is
therefore difﬁcult to assemble into larger biochemical networks,
competitive ABPP will inevitably accelerate the development of
novel inhibitors from natural products.
CONCLUSION
This mini review describes brieﬂy a limited number of approaches
involved in proﬁling serine hydrolases during viral infection and
assigning catalytic functions to previously uncharacterized serine
hydrolases. Visualization of the altered active serine hydrolase in
situ during viral disease progression, trying to fully understand
mechanisms of resistance and developing new antiviral therapeu-
tics and viral diagnostics will make the ABPP application more
worthwhile for the ﬁeld of virology.
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